San Diego, CA — (PRESS RELEASE JET) — 09/26/2017 — Intercept Pharmaceuticals Inc is under investigation over possible securities laws violations. The investigation was announced on behalf of investors of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) shares in connection with certain financial statements made by Intercept Pharmaceuticals Inc.

Investors who purchased shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT), have certain options and should contact the Shareholders Foundation at [email protected] or call 858-779-1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) concerning whether certain statements by Intercept Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

New York, NY based Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases.

On September 12, 2017, Intercept issued a letter warning physicians against overdosing patients with Ocaliva (obeticholic acid), the Company’s treatment for primary biliary cholangitis (“PBC”), advising them that the drug has been tied to liver injuries and death among patients suffering from PBC. Shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) declined on September 14, 2017 to $$85.97 per share.

Those who purchased shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
[email protected]

Powered by WPeMatico